STOCK Mr1^tm1Gfn Tcra^tm1Mjo Tap1^tm1Arp Cd74^tm1Doi Tg(Tcra-V19-J33)#Lantz Tg(Tcrb-V6)#Lantz/Orl

Status	Available to order
EMMA ID	EM:04509
International strain name	STOCK Mr1^tm1Gfn Tcra^tm1Mjo Tap1^tm1Arp Cd74^tm1Doi Tg(Tcra-V19-J33)#Lantz Tg(Tcrb-V6)#Lantz/Orl
Alternative name	iVa19/Vb6 Calpha ko TAP-/- ii -/- MR1+/-
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Tcra^tm1Mjo, Tg(Tcra-V19-J33)#Lantz, Tg(Tcrb-V6)#Lantz, Tap1^tm1Arp, Cd74^tm1Doi, Mr1^tm1Gfn
Gene/Transgene symbol	Tcra, Tg(Tcra-V19-J33)#Lantz, Tg(Tcrb-V6)#Lantz, Tap1, Cd74, Mr1

Information from provider

Provider	Olivier Lantz
Provider affiliation	immunology, Institut Curie
Genetic information	The VJ alpha (Va19-Ja33) and beta (Vb6) of MAIT cell hybridoma have been inserted into the shuttle vector described by Patten et al (J Immunol. 1993 Mar 15;150(6):2281-94.). The Va19-Ja33 transgene was introduced into B6 x DBA/2 eggs before being backcrossed 10 times to C57BL/6J. The Vb6 transgene was injected into C57BL/6 eggs.
Phenotypic information	The strain expresses a monoclonal population of MAIT cells.
Breeding history	It is a double transgenic (independently injected and thus not linked). It is immunodeficient and requires homozygous breeding.
References	Stepwise development of MAIT cells in mouse and human.;Martin Emmanuel, Treiner Emmanuel, Duban Livine, Guerri Lucia, Laude Hélène, Toly Cécile, Premel Virginie, Devys Anne, Moura Ivan C, Tilloy Florence, Cherif Stéphane, Vera Gabriella, Latour Sylvain, Soudais Claire, Lantz Olivier, ;2009;PLoS biology;7;e54; 19278296
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	yes
Immunocompromised	yes

Information from EMMA

Archiving centre	Institut de Transgenose, INTRAGENE, Orléans, France
Breeding at archiving centre	Males transgenic for Tg(Tcra-V19-J33)#Lantz (iVa) and Tg(Tcrb-V6)#Lantz (Vb6), homozygous knock-out for Tap1, Cd74 (ii) and Tcra (C alpha), homozygous or heterozygous knock-out for Mr1. For cryoarchiving females and males were crossed together.

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Immunodeficiency by defective expression of MHC class I / Orphanet_34592

IMPC phenotypes (gene matching)

decreased lymphocyte cell number / IMPC
increased neutrophil cell number / IMPC
decreased circulating creatinine level / IMPC
increased monocyte cell number / IMPC
increased eosinophil cell number / IMPC
decreased circulating phosphate level / IMPC
increased startle reflex / IMPC

MGI phenotypes (allele matching)

abnormal dendritic cell antigen presentation / MGI
abnormal antigen presentation / MGI
abnormal level of surface class II molecules / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
increased susceptibility to experimental autoimmune encephalomyelitis / MGI
abnormal B cell physiology / MGI
abnormal T cell number / MGI
decreased susceptibility to bacterial infection / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
increased T-helper 1 cell number / MGI
decreased susceptibility to bacterial infection induced morbidity/mortality / MGI
abnormal antigen presentation via MHC class I / MGI
defective assembly of class I molecules / MGI
defective intracellular transport of class I molecules / MGI
decreased level of surface class I molecules / MGI
decreased cytotoxic T cell cytolysis / MGI
absent CD8-positive, alpha-beta T cells / MGI
abnormal lymphocyte physiology / MGI
decreased double-negative T cell number / MGI
abnormal T cell physiology / MGI
decreased susceptibility to autoimmune diabetes / MGI
immune system phenotype / MGI
increased activated T cell number / MGI
rectal prolapse / MGI
abnormal colon morphology / MGI
abnormal intestinal mucosa morphology / MGI
enlarged spleen / MGI
spleen hyperplasia / MGI
colitis / MGI
increased T cell number / MGI
diarrhea / MGI
decreased T cell proliferation / MGI
increased gamma-delta T cell number / MGI
enlarged mesenteric lymph nodes / MGI
abnormal neuron proliferation / MGI
abnormal thymus cortex morphology / MGI
increased immunoglobulin level / MGI
increased IgE level / MGI
abnormal immune system organ morphology / MGI
increased autoantibody level / MGI
increased anti-double stranded DNA antibody level / MGI
increased anti-nuclear antigen antibody level / MGI
increased B cell number / MGI
abnormal T cell morphology / MGI
small Peyer's patches / MGI
increased IgG1 level / MGI
abnormal splenic cell ratio / MGI
absent thymus medulla / MGI
enlarged thymus cortex / MGI
abnormal kidney morphology / MGI
increased urine protein level / MGI

MGI phenotypes (gene matching)

decreased cell proliferation / MGI
decreased body size / MGI
arrested B cell differentiation / MGI
decreased IgM level / MGI
abnormal antigen presentation / MGI
abnormal B cell differentiation / MGI
abnormal professional antigen presenting cell physiology / MGI
abnormal dendritic cell antigen presentation / MGI
increased susceptibility to experimental autoimmune encephalomyelitis / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
abnormal positive T cell selection / MGI
decreased B cell number / MGI
abnormal antigen presentation via MHC class II / MGI
abnormal level of surface class II molecules / MGI
defective assembly of class II molecules / MGI
decreased B cell proliferation / MGI
abnormal T cell proliferation / MGI
decreased T cell proliferation / MGI
cachexia / MGI
increased T cell proliferation / MGI
immune system phenotype / MGI
hematopoietic system phenotype / MGI
abnormal T-helper 1 physiology / MGI
decreased susceptibility to type IV hypersensitivity reaction / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
increased immature B cell number / MGI
decreased interferon-gamma secretion / MGI
decreased interleukin-2 secretion / MGI
abnormal lymph node cell ratio / MGI
abnormal B cell physiology / MGI
increased susceptibility to experimental autoimmune encephalomyelitis / MGI
abnormal T cell number / MGI
absent CD8-positive, alpha-beta T cells / MGI
impaired hematopoiesis / MGI
abnormal antigen presentation / MGI
abnormal antigen presentation via MHC class I / MGI
defective assembly of class I molecules / MGI
defective intracellular transport of class I molecules / MGI
decreased level of surface class I molecules / MGI
decreased susceptibility to bacterial infection / MGI
increased susceptibility to viral infection / MGI
abnormal dendritic cell antigen presentation / MGI
abnormal lymphocyte physiology / MGI
decreased cytotoxic T cell cytolysis / MGI
decreased double-negative T cell number / MGI
immune system phenotype / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
increased T-helper 1 cell number / MGI
decreased susceptibility to bacterial infection induced morbidity/mortality / MGI
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number / MGI
decreased CD8-positive, alpha-beta memory T cell number / MGI
abnormal large intestine morphology / MGI
crypts of Lieberkuhn abscesses / MGI
rectal prolapse / MGI
abnormal colon morphology / MGI
abnormal intestinal mucosa morphology / MGI
intestinal ulcer / MGI
abnormal liver morphology / MGI
enlarged spleen / MGI
spleen hyperplasia / MGI
decreased thymocyte number / MGI
chronic diarrhea / MGI
decreased IgG level / MGI
thymus hypoplasia / MGI
arrested T cell differentiation / MGI
increased activated T cell number / MGI
premature death / MGI
abnormal respiratory system morphology / MGI
abnormal kidney morphology / MGI
abnormal T cell differentiation / MGI
abnormal thymus cortex morphology / MGI
abnormal double-negative T cell morphology / MGI
increased susceptibility to bacterial infection / MGI
abnormal T cell physiology / MGI
increased immunoglobulin level / MGI
increased IgE level / MGI
abnormal immune system organ morphology / MGI
colitis / MGI
increased urine protein level / MGI
abnormal cytokine secretion / MGI
no phenotypic analysis / MGI
abnormal intestinal goblet cell morphology / MGI
increased autoantibody level / MGI
abnormal T cell subpopulation ratio / MGI
increased anti-double stranded DNA antibody level / MGI
increased anti-nuclear antigen antibody level / MGI
decreased susceptibility to autoimmune diabetes / MGI
increased B cell number / MGI
increased T cell number / MGI
abnormal response to infection / MGI
diarrhea / MGI
decreased double-positive T cell number / MGI
decreased T cell proliferation / MGI
immune system phenotype / MGI
abnormal response to transplant / MGI
abnormal NK T cell morphology / MGI
abnormal T cell morphology / MGI
increased NK T cell number / MGI
absent T cells / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
small Peyer's patches / MGI
increased gamma-delta T cell number / MGI
increased gamma-delta intraepithelial T cell number / MGI
increased mature gamma-delta T cell number / MGI
enlarged mesenteric lymph nodes / MGI
decreased IgG2a level / MGI
increased IgG1 level / MGI
increased interferon-gamma secretion / MGI
increased interleukin-10 secretion / MGI
increased interleukin-2 secretion / MGI
increased interleukin-4 secretion / MGI
abnormal T cell receptor alpha chain V-J recombination / MGI
abnormal splenic cell ratio / MGI
decreased splenocyte number / MGI
abnormal neuron proliferation / MGI
absent thymus medulla / MGI
enlarged thymus cortex / MGI

Literature references

Stepwise development of MAIT cells in mouse and human.;Martin Emmanuel, Treiner Emmanuel, Duban Livine, Guerri Lucia, Laude Hélène, Toly Cécile, Premel Virginie, Devys Anne, Moura Ivan C, Tilloy Florence, Cherif Stéphane, Vera Gabriella, Latour Sylvain, Soudais Claire, Lantz Olivier, ;2009;PLoS biology;7;e54; 19278296

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

STOCK Mr1tm1Gfn Tcratm1Mjo Tap1tm1Arp Cd74tm1Doi Tg(Tcra-V19-J33)#Lantz Tg(Tcrb-V6)#Lantz/Orl